Literature DB >> 1753109

Antigen detection in pneumococcal pneumonia.

M Farrington1, D Rubenstein.   

Abstract

Streptococcus pneumoniae remains the commonest proven cause of community-acquired pneumonia in patients admitted to hospital, but no currently available diagnostic method can be regarded as a gold standard. Microscopy of sputum is usually considered insensitive and poorly specific, and more invasively-obtained specimens are not routinely collected. Cultures of blood and respiratory secretions, and countercurrent immunoelectrophoresis (CIE) and particle agglutination-based assays for capsular polysaccharides in serum and urine specimens, are specific but less than ideally sensitive. Some workers have reported specificity problems when immunoassays are applied to respiratory secretions. New diagnostic methods include detection of pneumococcal C polysaccharide in sputum and urine by ELISA and particle-agglutination assays, and these appear promisingly sensitive and specific in preliminary studies. Clinical assessments are now required to define the role of these techniques in guiding the treatment of individual patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1753109     DOI: 10.1016/0163-4453(91)91900-i

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  11 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Diagnosis of invasive pneumococcal infection by serotype-specific urinary antigen detection.

Authors:  John P Leeming; Keith Cartwright; Rhonwen Morris; Siobhan A Martin; Michael D Smith
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital.

Authors:  R Bohte; R van Furth; P J van den Broek
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

4.  Pneumococcal community-acquired pneumonia in 148 hospitalized adult patients.

Authors:  A Porath; F Schlaeffer; N Pick; M Leinonen; D Lieberman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

5.  Purification and seroreactivity of pneumococcal surface adhesin A (PsaA).

Authors:  J A Tharpe; H Russell
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

6.  Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine.

Authors:  Michael W Pride; Susanne M Huijts; Kangjian Wu; Victor Souza; Sherry Passador; Chunyan Tinder; Esther Song; Arik Elfassy; Lisa McNeil; Ronald Menton; Roger French; Janice Callahan; Chris Webber; William C Gruber; Marc J M Bonten; Kathrin U Jansen
Journal:  Clin Vaccine Immunol       Date:  2012-06-06

7.  Pneumococcal serotypes causing pediatric meningitis in Turkey: application of a new technology in the investigation of cases negative by conventional culture.

Authors:  M Ceyhan; I Yildirim; C L Sheppard; R C George
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-01-20       Impact factor: 3.267

8.  Comparison of two urinary antigen tests for establishment of pneumococcal etiology of adult community-acquired pneumonia.

Authors:  Kristoffer Strålin; Margit Staum Kaltoft; Helle Bossen Konradsen; Per Olcén; Hans Holmberg
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  Value of bacterial antigen detection in the diagnostic yield of transthoracic needle aspiration in severe community acquired pneumonia.

Authors:  F Bella; J Tort; M A Morera; J Espaulella; J Armengol
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

10.  Pneumococcal urinary antigen positivity in healthy colonized children: is it age dependent?

Authors:  Zuzana Vančíková; Milan Trojánek; Helena Zemličková; Zuzana Blechová; Jitka Motlová; Jana Matějková; Otakar Nyč; Jerry John; Marek Malý; Vilma Marešová
Journal:  Wien Klin Wochenschr       Date:  2013-08-09       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.